References
1)
Baig
AM,
Khaleeq
A,
Ali
U,
Syeda
H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue
Distribution, Host-Virus Interaction, and Proposed Neurotropic
Mechanisms . ACS ChemNeuroscienc. 2020 Mar 13. doi:
10.1021/acschemneuro.0c00122
2)
Liu
Z,
Xiao
X,
Wei
X,
Li
J,
Yang
,
Tan
H,
Zhu
J,
Zhang
Q,
Wu
J,
Liu
L.JComposition and divergence of coronavirus spike proteins and host
ACE2 receptors predict potential intermediate hosts of SARS-CoV.MedVirol. 2020 Feb 26. doi: 10.1002/jmv.25726. 2.
3)
Cascella
M,
Rajnik
M,
Cuomo
A,
Dulebohn
SC,
Di
Napoli R. Features, Evaluation and Treatment Coronavirus
(COVID-19). StatPearls [Internet]. Treasure Island (FL):
StatPearls Publishing;2020 Mar 8.
4)
Meo
SA,
Alhowikan
AM,
Al-Khlaiwi
T,
Meo
IM,
Halepoto
DM,
Iqbal
M,
Usmani
AM,
Hajjar
W,
Ahmed
N. Novel coronavirus 2019-nCoV: prevalence, biological and
clinical characteristics comparison with SARS-CoV and MERS-CoV .
Eur Rev Med
Pharmacol Sci. 2020 Feb;24(4):2012-2019.
5)
Ashour
HM,
Elkhatib
WF,
Rahman
MM,
Elshabrawy
HA. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2)
in Light of Past Human Coronavirus Outbreaks.Pathogens. 2020 Mar
4;9(3). pi: E186.
6)
Walls
AC
,Park
YJ
,Tortorici
MA,
Wall
A,
McGuire
AT,
Veesler
D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
Glycoprotein.Cell.2020 Mar 6.
pii: S0092-8674(20)30262-2.
7)
Imai
Y,
Kuba
K,
Penninger
JM. Angiotensin-convertingenzyme 2 in acute
respiratorydistresssyndrome.Cell Mol Life
Sci.2007 Aug;64(15):2006-12.
8)
Zou
X,
Chen
K,
Zou
J,
Han
P,
Hao
J,
Han
Z. Single-cell RNA-seq data analysis on the receptor ACE2
expression reveals the potential risk of different human organs
vulnerable to 2019-nCoV infection.Front Med. 2020 Mar
12. doi: 10.1007/s11684-020-0754-0. [Epub ahead of print]
9)
Batlle
D,
Wysocki
J,
Satchell
K. Soluble angiotensin-converting enzyme 2: a potential approach for
coronavirus infection therapy?Clin Sci (Lond).
2020 Mar 13;134(5):543-545. doi: 10.1042/CS20200163.
10)Tan
WSD,
Liao
W,
Zhou
S,
Mei
D,
Wong
WF. Targeting the renin-angiotensin system as novel therapeutic
strategy for pulmonary diseases.CurrOpinPharmacol.
2018 Jun;40:9-17. doi: 10.1016/j.coph.2017.12.002. Epub 2017 Dec 27.
11)
Patel
S,
Rauf
A,
Khan
H,
Abu-Izneid
T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system
for homeostasis and pathologies.BiomedPharmacother.
2017 Oct;94:317-325. doi: 10.1016/j.biopha.2017.07.091. Epub 2017 Jul
31.
12)
Lindgren
BR,
AnderssonRG.Angiotensin-converting
enzyme inhibitors and their influence on inflammation, bronchial
reactivity and cough. A
researchreview. MedToxicolAdverseDrugExp.1989
Sep-Oct;4(5):369-80.
13)
Kim
J,
Choi
SM,
Lee
J,
Park
YS,
Lee
CH,
Yim
JJ,
Yoo
CG,
Kim
YW,
Han
SK,
Lee
SM.Effect of Renin-Angiotensin System Blockage in Patients with Acute
Respiratory Distress Syndrome:A Retrospective Case Control
Study.Korean J Crit
Care Med.2017 May;32(2):154-163. doi: 10.4266/kjccm.2016.00976. Epub
2017 May 31.
14) Haibo Zhang, Josef M. Penninger, Yimin Li, Nanshan Zhong&Arthur
S.Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor:
molecular mechanisms and potential therapeutic
target. SlutskyIntensive
Care Medicine (2020).
15)
MirabitoColafella
KM,
Bovée
DM,
Danser
AHJ.The renin-angiotensin-aldosterone system and its therapeutic
targets. Exp Eye
Res. 2019 Sep;186:107680. doi: 10.1016/j.exer.2019.05.020. Epub 2019
May 23.
16) Slabý A, Zák A. CasLekCesk.Renin,
prorenin, and the direct renin inhibitor aliskiren. 2010;149(2):55-60.
Review. Czech.
17) Aulakh GK, Sodhi RK, Singh M.An update on
non-peptide angiotensin receptor antagonists and related RAAS
modulators. Life Sci. 2007 Aug 2;81(8):615-39. Epub 2007 Jun 28.
Review.
18)
Ding
W,
Li
X,
Wu
W,He
H,
Li
Y,
Gao
L,
Gan
L,
Wang
M,
Ou
S,
Liu
J. Aliskiren inhibits angiotensin II/angiotensin 1-7(Ang
II/Ang1-7) signal pathway in rats with diabetic nephropathy .
19) Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of
critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a
single-centered, retrospective, observational study. Lancet Respir Med
2020; published online Feb 24.
20) Guan W, Ni Z, Hu Y, et al. Clinical characteristics of
coronavirus disease 2019 in China. N Engl J Med 2020; published online
Feb 28.
21) Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of
140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy 2020;
published online Feb 19.
22) Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition
by novel coronavirus from Wuhan: An analysis based on decade-long
structural studies of SARS . J Virology 2020; published online Jan 29.
23) Li XC, Zhang J, Zhuo JL. Lei Fang, George Karakiulakis, Michael RothThevasoprotective axes of the renin-angiotensin system:
physiological relevance and therapeutic implications in cardiovascular,
hypertensive are patients with hypertension and diabetes mellitus at
increased risk for COVID-19 infection? Lancet Respir Med 2020Published
OnlineMarch 11, 2020.
24)
Andersson
RG,
Persson
K. ACE inhibitors and their influence on inflammation, bronchial
reactivity and cough.EurHeart J. 1994
Aug;15 Suppl C:52-6.
25)Gurwitz
D. Angiotensin receptor blockers as tentative SARS-CoV-2
therapeutics. Drug
Dev Res. 2020 Mar 4. doi: 10.1002/ddr.21656.
26) Drug Saf. 1996
Jul;15(1):72-8.ACE inhibitor-induced cough and bronchospasm. Incidence,
mechanisms and management.
Overlack
A.